Effects of Torcetrapib in Patients at High Risk for Coronary Events
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib. METHODS: We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk. The patients received either torcetrapib plus atorvastatin or atorvastatin alone. The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina. RESULTS: At 12 months in patients who received torcetrapib, there was an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, as compared with baseline (P<0.001 for both comparisons), in addition to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P<0.001 for all comparisons). There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P=0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P=0.006). Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose reduction in potassium or increase in bicarbonate was greater than the median change. CONCLUSIONS: Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition. (ClinicalTrials.gov number, NCT00134264 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, BIA 10-2474 (Section 7.3) and torcetrapib (Section 7.5) are off-target toxicities that surfaced only at clinical exposures.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor designed to raise HDL-cholesterol, produced favourable surrogate-biomarker changes in trials but increased all-cause mortality in the ILLUMINATE outcome study.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“The mortality signal traced not to CETP inhibition itself but to off-target hemodynamic effects, including aldosterone elevation, blood pressure increases, and electrolyte shifts independent of the lipid mechanism [25].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“three large RCTs of cholesterol ester transfer protein inhibitors (dalcetrapib, evacetrapib, and torcetrapib) did not improve CV outcomes despite substantial increases in plasma HDL-C levels”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [20]
In the citing paper
“Furthermore, phase 3 trials of cholesteryl ester transfer protein inhibitors have shown that reducing LDL-C does not necessarily prevent CVD.”
From Saturated Fat Restriction for Cardiovascular Disease Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials (2025) · cites this paper as [8]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Self-citationEffect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966
Self-citationCholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054658.91146.64 · Cited by 870
Self-citationEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein, J. J. P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071359 · Cited by 658
Self-citationHDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
Self-citationHigh-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Bots, M. L., Visseren, F. L., Evans, G. W., Riley, W. A., Revkin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., Grobbee, D. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61088-5 · Cited by 461
Self-citation
Cited by
Items 601–700 of 1,017
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55-REVEAL Collaborative Group, Sammons, E. L., Hopewell, J. C., Chen, F., Stevens, W., Wallendszus, K., Valdés‐Márquez, E., Dayanandan, R., Knott, C., Murphy, K., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab863 · Cited by 67
“The ILLUMINATE (Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events) trial was terminated because of excesses of cardiac events and death with torcetrapib, which have been attributed to various off-target drug effects on blood pressure.(7) The Dal-OUTCOMES (Effects of Dalcetrapib…”
Self-citationNew and Emerging Risk Factors for Coronary Heart Disease
Akhabue, E., Thiboutot, J. P., Cheng, J.-W., Lerakis, S., Vittorio, T. J., Christodoulidis, G., Grady, K. M., & Kosmas, C. E. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31828aab45 · Cited by 71
“This increase in morbidity and mortality was attributed to off target hyperaldosteronism, caused by torcetrapib.(108) However, dalcetrapib, another cholesteryl ester transfer protein inhibitor with no renin-angiotensin-aldosterone system–inducing properties, also failed to reduce the risk of recurrent cardiovascular e…”
BackgroundEndothelial FAK as a therapeutic target in disease
Infusino, G. A., & Jacobson, J. R. (2012) · Microvascular Research · doi:10.1016/j.mvr.2011.09.011 · Cited by 61
Universal Screening and Drug Treatment of Dyslipidemia in Children and Adolescents
Psaty, B. M., & Rivara, F. P. (2011) · JAMA · doi:10.1001/jama.2011.1916 · Cited by 61
Hager, L., Li, L., Pun, H., Liu, L., Hossain, M. A., Maguire, G. F., Naples, M., Baker, C., Magomedova, L., Tam, J., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.340919 · Cited by 61
Evidence of a Polygenic Origin of Extreme High-Density Lipoprotein Cholesterol Levels
Motazacker, M. M., Peter, J., Treskes, M., Shoulders, C. C., Kuivenhoven, J. A., & Hovingh, G. K. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301505 · Cited by 61
Kingwell, B. A., & Chapman, M. J. (2013) · Circulation · doi:10.1161/circulationaha.113.002683 · Cited by 68
Hirata, A., Okamura, T., Sugiyama, D., Kuwabara, K., Kadota, A., Fujiyoshi, A., Miura, K., Okuda, N., Ohkubo, T., Okayama, A., et al. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.33449 · Cited by 61
Arsenault, B. J., Petrides, F., Tabet, F., Bao, W., Hovingh, G. K., Boekholdt, S. M., Ramin‐Mangata, S., Meilhac, O., DeMicco, D. A., Rye, K., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.001 · Cited by 63
“Noteworthy, the use of torcetrapib in ILLUMINATE was found to have serious adverse off-target effects with an increase in cardiovascular events and related deaths.(18) We randomly selected 594 patients receiving torcetrapib and atorvastatin matched in a 1:2 ratio to 1151 patients receiving placebo and atorvastatin.”
MethodSelf-citationTherapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk
Masson, W., Lobo, M., Siniawski, D., Huerín, M., Molinero, G., Valéro, R., & Nogueira, J. P. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.02.005 · Cited by 61
“The first CETP inhibitor, torcetrapib, was discontinued due to an increase in cardiovascular events that was attributed to off-target adverse effects [5].”
BackgroundDokras, A. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.10.027 · Cited by 68
Stamatikos, A., Dronadula, N., Ng, P., Palmer, D., Knight, E., Wacker, B. K., Tang, C., Kim, F., & Dichek, D. A. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.120 · Cited by 60
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19
Talasaz, A. H., Sadeghipour, P., Aghakouchakzadeh, M., Dreyfus, I., Kakavand, H., Ariannejad, H., Gupta, A., Madhavan, M. V., Tassell, B. W. V., Jiménez, D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.021 · Cited by 65
“In the ILLUMINATE (Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events) trial, torcetrapib (another CETP inhibitor) had favorable effects on lipids but showed an increase in death due to sepsis and increased systolic blood pressure (36).”
Sarraju, A., Brennan, D. M., Hayden, K., Stronczek, A., Goldberg, A. C., Michos, E. D., McGuire, D. K., Mason, D., Tercek, G., Nicholls, S. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00721-4 · Cited by 66
Self-citationJohns, D. G., Duffy, J., Fisher, T. S., Hubbard, B. K., & Forrest, M. J. (2012) · Drugs · doi:10.2165/11599310-000000000-00000 · Cited by 61
Targeting metabolic disturbance in the diabetic heart
Fuentes-Antrás, J., Picatoste, B., Ramírez, E., Egido, J., Tuñón, J., & Lorenzo, Ó. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0173-8 · Cited by 60
“Statins Dependence on plasma lipid reduction and vascular remodelling [41,42]”
BackgroundHunter, W. G., McGarrah, R. W., Kelly, J. P., Khouri, M. G., Craig, D. M., Haynes, C. S., Felker, G. M., Hernandez, A. F., Velazquez, E. J., Kraus, W. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.059 · Cited by 61
Ford, J., Lawson, M., Fowler, D., Maruyama, N., Mito, S., Tomiyasu, K., Kinoshita, S., Suzuki, C., Kawaguchi, A., Round, P., et al. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12380 · Cited by 61
Self-citationInsight into rheumatological cause and effect through the use of Mendelian randomization
Robinson, P. C., Choi, H. K., Do, R., & Merriman, T. R. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.102 · Cited by 62
Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
Gareri, C., Polimeni, A., Giordano, S., Tammè, L., Curcio, A., & Indolfi, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133884 · Cited by 59
Chirovsky, D. R., Fedirko, V., Cui, Y. A., Sazonov, V., & Barter, P. J. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e32832c8891 · Cited by 63
Self-citationSpotlight on HDL-raising therapies: insights from the torcetrapib trials
Kontush, A., Guérin, M., & Chapman, M. J. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1191 · Cited by 67
Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011
Bikdeli, B., Punnanithinont, N., Akram, Y., Lee, I., Desai, N. R., Ross, J. S., & Krumholz, H. M. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005285 · Cited by 59
Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids
Kris‐Etherton, P. M., Richter, C. K., Bowen, K. J., Skulas‐Ray, A. C., Jackson, K. H., Petersen, K. S., & Harris, W. S. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-3-171 · Cited by 69
Dysfunctional HDL: From Structure-Function-Relationships to Biomarkers
Riwanto, M., Rohrer, L., von Eckardstein, A., & Landmesser, U. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_10 · Cited by 68
“…its Impact in Atherosclerotic Events (ILLUMINATE) trial testing the impact of the CETP inhibitor torcetrapib on clinical outcome showed increased risk of mortality and morbidity in patients at high risk for coronary events, despite a substantial increase of HDL-C levels (Barter et al. 2007).”
BackgroundDoğan, S., Duivenvoorden, R., Grobbee, D. E., Kastelein, J. J. P., Shear, C. L., Evans, G., Visseren, F. L. J., Bots, M. L., & Groups, O. B. O. T. R. 1. A. R. 2. S. (2010) · Annals of Medicine · doi:10.3109/07853890.2010.499132 · Cited by 58
“Although the event trial with atorvastatin and torcetrapib showed increased risk in the torcetrapib arm as compared to atorvastatin monotherapy (36), we decided to rank the ultrasound protocols as if treatment with torcetrapib was to slow down CIMT progression.”
BackgroundSelf-citationWalley, K. R., Francis, G. A., Opal, S. M., Stein, E. A., Russell, J. A., & Boyd, J. H. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-0876ci · Cited by 66
Treating Coronary Disease and the Impact of Endothelial Dysfunction
Matsuzawa, Y., Guddeti, R. R., Kwon, T.-G., Lerman, L. O., & Lerman, A. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2014.10.004 · Cited by 57
Brunzell, J. D., Zambon, A., & Deeb, S. S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.008 · Cited by 72
“The CETP inhibitor, torcetrapid, increased HDL cholesterol without a decrease in atherosclerosis [64].”
BackgroundShinkai, H. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s25238 · Cited by 70
“Despite the favorable lipid changes in the torcetrapib group, the rate of major cardiovascular events increased by 25% and the rate of death from cardiovascular causes increased by 40%.(28) Torcetrapib was also associated with an increase of 5.”
BackgroundTargeting paraoxonase-1 in atherosclerosis
Mackness, M., & Mackness, B. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.790367 · Cited by 58
Franssen, R., Sankatsing, R. R., Hassink, E., Hutten, B., Ackermans, M., Brinkman, K., Oesterholt, R., Arenas-Pinto, A., Storfer, S., Kastelein, J., et al. (2009) · Arteriosclerosis, Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.192088 · Cited by 56
Self-citationOwen, D. R., Wood, D. M., Archer, J. R. H., & Dargan, P. I. (2015) · Drug and Alcohol Review · doi:10.1111/dar.12356 · Cited by 58
Puri, R., Nissen, S. E., Somaratne, R. M., Cho, L., Kastelein, J. J. P., Ballantyne, C. M., Köenig, W., Anderson, T. J., Yang, J., Kassahun, H., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.01.019 · Cited by 66
Self-citationNew Era of Lipid-Lowering Drugs
Barter, P. J., & Rye, K. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012203 · Cited by 65
Self-citationSaito, I., Yamagishi, K., Kokubo, Y., Yatsuya, H., Iso, H., Sawada, N., Inoue, M., & Tsugane, S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.08.032 · Cited by 61
Otvos, J. D., Guyton, J. R., Connelly, M. A., Akapame, S., Bittner, V., Kopecky, S. L., Lacy, M., Marcovina, S. M., Muhlestein, J. B., & Boden, W. E. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.002 · Cited by 61
Mazidi, M., Mikhailidis, D. P., & Banach, M. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.095 · Cited by 65
Tanaka, S., Stern, J., Bouzid, D., Robert, T., Dehoux, M., Snauwaert, A., Zappella, N., Cournot, M., Lortat‐Jacob, B., Augustin, P., et al. (2021) · Annals of Intensive Care · doi:10.1186/s13613-021-00800-0 · Cited by 59
Dong, B., Singh, A. B., Fung, C., Kan, K. K. W., & Liu, J. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.05.931 · Cited by 62
“The TOR program was terminated early due to its off-target effects on inducing aldosterone and cortisol production that were the underline causes for excess CVD endpoints and mortality in the TOR group versus placebo [19].”
BackgroundHiura, Y., Shen, C.-S., Kokubo, Y., Okamura, T., Morisaki, T., Tomoike, H., Yoshida, T., Sakamoto, H., Goto, Y., Nonogi, H., et al. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1101 · Cited by 57
Tehrani, D. M., Gardin, J. M., Yanez, D., Hirsch, C. H., Lloyd‐Jones, D. M., Stein, P. K., & Wong, N. D. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.08.036 · Cited by 59
“Also, while there are abundant epidemiologic evidence for the inverse association between HDL-C and CHD risk, drugs which increase HDL-C have shown little benefit for coronary risk [24,25].”
BackgroundTan, J. T. M., Prosser, H. C. G., Vanags, L. Z., Monger, S., Ng, M., & Bursill, C. A. (2013) · The FASEB Journal · doi:10.1096/fj.13-233874 · Cited by 63
Fayad, Z. A., Mani, V., Woodward, M., Kallend, D. G., Bansilal, S., Pozza, J., Burgess, T., Fuster, V., Rudd, J. H. F., Tawakol, A. A., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.05.006 · Cited by 57
Murphy, A. J., Funt, S., Gorman, D., Tall, A. R., & Wang, N. (2013) · Circulation Research · doi:10.1161/circresaha.113.301112 · Cited by 57
Self-citationHypertriglyceridemia and Cardiovascular Diseases: Revisited
Han, S. H., Nicholls, S. J., Sakuma, I., Zhao, D. H., & Koh, K. K. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.2.135 · Cited by 70
Williams, S. A., Murthy, A. C., DeLisle, R. K., Hyde, C., Malarstig, A., Ostroff, R., Weiss, S. J., Segal, M. R., & Ganz, P. (2018) · Circulation · doi:10.1161/circulationaha.117.028213 · Cited by 57
Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management
Mytilinaiou, M. G., Kyrou, I., Khan, M., Grammatopoulos, D. K., & Randeva, H. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00707 · Cited by 77
“9% in a RCT comparing the combination of torcetrapib and atorvastatin to atorvastatin alone, but this trial was terminated due to increased morbidity and mortality of unspecified pathogenesis (Barter et al., 2007).”
BackgroundRevealing the effect of CETP inhibition in cardiovascular disease
Holmes, M. V., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.156 · Cited by 56
Functional assessments in repeat-dose toxicity studies: the art of the possible
Redfern, W. S., Ewart, L. C., Lainée, P., Pinches, M., Robinson, S., & Valentin, J. (2013) · Toxicology Research · doi:10.1039/c3tx20093k · Cited by 57
Lipids, blood pressure and kidney update 2015
Banach, M., Aronow, W. S., Serban, M.-C., Rysz, J., Voroneanu, L., & Covic, A. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0169-0 · Cited by 56
“%) and total HDL-C particles (+11.2 % vs +1.4 %, p <0.01). in alirocumab group as compared to placebo group [20].”
BackgroundInfluentialNew insights into lipopolysaccharide inactivation mechanisms in sepsis
Pérez-Hernández, E. G., Delgado-Coello, B., Luna-Reyes, I., & Mas-Oliva, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111890 · Cited by 56
Kühnast, S., Fiocco, M. F., van der Hoorn, J. W. A., Princen, H. M. G., & Jukema, J. W. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.089 · Cited by 63
Wang, H., Liu, J., Zhao, H., Fu, X., Shang, G., Zhou, Y., Yu, X., Zhao, X., Wang, G., & Shi, H. (2013) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2013.06.003 · Cited by 57
Role of HDL in Those with Diabetes
Santos‐Gallego, C. G., & Rosenson, R. S. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0512-5 · Cited by 65
Tom, W. L., Playford, M. P., Admani, S., Natarajan, B., Joshi, A. A., Eichenfield, L. F., & Mehta, N. N. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.385 · Cited by 58
“…are inversely correlated with CVD events, therapies increasing HDL-c have not shown substantial effect in decreasing their risk, sparking the concept that HDL function is more important to disease outcome than the quantity of HDL (Barter et al., 2007; Khera et al., 2013; Rohatgi et al., 2014).”
BackgroundmicroRNAs in lipoprotein and lipid metabolism: from biological function to clinical application
Desgagné, V., Bouchard, L., & Guérin, R. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0575 · Cited by 57
Detrimental Effect of Hypercholesterolemia on High-Density Lipoprotein Particle Remodeling in Pigs
Padró, T., Cubedo, J., Camino-López, S., Béjar, M. T., Ben‐Aicha, S., Mendieta, G., Escolá‐Gil, J. C., Escate, R., Gutiérrez, M., Casaní, L., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.05.018 · Cited by 58
Present therapeutic role of cholesteryl ester transfer protein inhibitors
Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.028 · Cited by 57
The Use of Biomarkers in Human Pharmacology (Phase I) Studies
Cohen, A. F., Burggraaf, J., van Gerven, J. M. A., Moerland, M., & Groeneveld, G. J. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135918 · Cited by 55
“These effects were potentially detectable in animals (10) and were seen in earlier studies (11) and even in late clinical studies (9, 12).”
BackgroundTreatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Khavandi, M., Duarte, F., Ginsberg, H. N., & Reyes‐Soffer, G. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0818-1 · Cited by 66
Masana, L., Ibarretxe, D., & Plana, N. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01326-w · Cited by 54
Prenner, S. B., Mulvey, C. K., Ferguson, J. F., Rickels, M. R., Bhatt, A. B., & Reilly, M. P. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.07.008 · Cited by 61
“Renewed interest in TGRL as causal and therapeutic targets in heart disease has been driven by large epidemiological studies [1e4], trial failures of HDL-C therapies in CVD [21], and recent genomic work suggesting that TGRL may be causal in atherosclerotic CVD [6e8].”
ResultOliveira, H. C. F., & de Faria, E. C. (2011) · IUBMB Life · doi:10.1002/iub.448 · Cited by 57
“Increased LDL-cholesterol Decreased HDL-cholesterol (16) Anti-atherogenic mechanisms Increased efficiency of the LCAT reaction (Oliveira et al.”
BackgroundInfluentialMechanistic systems modeling to guide drug discovery and development
Schmidt, B. J., Papin, J. A., & Musante, C. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.09.003 · Cited by 65
“Atherosclerotic Events, ILLUMINATE) found an increase in blood pressure and mortality in the group treated with combination atorvastatin and torcetrapib [48].”
BackgroundMayer, E. L., Dallabrida, S. M., Rupnick, M. A., Redline, W., Hannagan, K., Ismail, N. S., Burstein, H. J., & Beckman, J. A. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.168120 · Cited by 57
Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future
Weber, C., Badimón, L., Mach, F., & van der Vorst, E. P. C. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0814 · Cited by 60
“The first trial using torcetrapib (ILLUMINATE) was terminated early due to off-target effects leading to increased mortality rates in the active treatment group (36).”
BackgroundTargeting Non-coding RNA in Vascular Biology and Disease
Hung, J., Miscianinov, V., Sluimer, J. C., Newby, D. E., & Baker, A. H. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01655 · Cited by 57
“Trials using niacin and CEPTB inhibitors, such as torcetrapib, have shown no benefit and in fact, the ILLUMINATE trial was stopped early due an increase in all cause mortality in the treatment group (Barter et al., 2007; Boden et al., 2011).”
MethodZhao, Z., Du, S., Shen, S., Luo, P., Ding, S., Wang, G., & Wang, L. (2019) · Medicine · doi:10.1097/md.0000000000014400 · Cited by 54
“Several lipid-lowering agents, such as torcetrapib,([6]) fenofibrate,([7]) and niacin,([8]) had been developed to fulfill lipid management need, but none demonstrated a benefit in terms of CV outcomes, despite they showing salutary effects in improving lipid levels.”
BackgroundA Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease
Zhao, Q., Wang, J., Miao, Z., Zhang, N. R., Hennessy, S., Small, D. S., & Rader, D. J. (2021) · eLife · doi:10.7554/elife.58361 · Cited by 58
“There has been a heated debate on the role of HDL particles in CAD in recent years following the failure of several trials for CETP inhibitors (Barter et al., 2007; Schwartz et al., 2012; Lincoff et al., 2017) and recombinant ApoA1 (Nicholls et al.”
BackgroundTarget Populations for Novel Triglyceride-Lowering Therapies
Nordestgaard, A. T., Tybjærg-Hansen, A., Mansbach, H., Kersten, S., Nordestgaard, B. G., & Rosenson, R. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.035 · Cited by 54
Potential savings without compromising the quality of care
Norman, C., Zarrinkoub, R., Hasselström, J., Godman, B., Granath, F. N., & Wettermark, B. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02129.x · Cited by 57
Lipid-Lowering Drugs in Ischemic Stroke Prevention and Their Influence on Acute Stroke Outcome
Fuentes, B., Martínez‐Sánchez, P., & Díez‐Tejedor, E. (2009) · Cerebrovascular Diseases · doi:10.1159/000200450 · Cited by 56
“However, studies specifically designed to evaluate the impact of fibrates on stroke prevention are needed to get definite conclusions.On the other hand, the ILLUMINATE (Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events) trial that tested torcetrapib (a potent inhibitor of chole…”
BackgroundImaging Plaques to Predict and Better Manage Patients With Acute Coronary Events
García‐García, H. M., Jang, I., Serruys, P. W. J. C., Kovacic, J. C., Narula, J., & Fayad, Z. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.302745 · Cited by 60
Pathophysiology of diabetic dyslipidemia:implications for atherogenesis and treatment
Sugden, M., & Holness, M. (2011) · Clinical Lipidology · doi:10.2217/clp.11.32 · Cited by 62
Seo, S. M., Choo, E. H., Koh, Y. S., Park, M., Shin, D.-I., Choi, Y. S., PARK, H., Kim, D. B., Her, S., Lee, J. M., et al. (2011) · Heart · doi:10.1136/hrt.2011.225466 · Cited by 58
Blauw, L. L., Li‐Gao, R., Noordam, R., de Mutsert, R., Trompet, S., Berbée, J. F. P., Wang, Y., van Klinken, J. B., Christen, T., van Heemst, D., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.117.002034 · Cited by 58
Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation
Tall, A. R. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.004 · Cited by 60
Self-citationPenson, P. E., Long, D. L., Howard, G., Howard, V. J., Jones, S. R., Martin, S. S., Mikhailidis, D. P., Muntner, P., Rizzo, M., Rader, D. J., et al. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy198 · Cited by 56
“Despite early promise,(3) recent trials with niacin or cholesteryl ester transfer protein (CETP) inhibitors failed to demonstrate that treatment to raise HDL-C resulted in improved cardiovascular (CV) health outcomes.(4,5) A study employing Mendelian randomization demonstrated that several polymorphisms, which raised…”
BackgroundHigh-Density Lipoprotein Cholesterol and All-Cause and Cause-Specific Mortality Among the Elderly
Li, Z., Lv, Y., Zhong, W.-F., Gao, X., Kraus, V. B., Zou, M., Zhang, X.-R., Li, F.-R., Yuan, J.-Q., Shi, X., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02511 · Cited by 60
“mortality (4), despite the ability of these treatments to in-”
BackgroundAn Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias
Rached, F. H., Chapman, M. J., & Kontush, A. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.85 · Cited by 57
Furtado, J. D., Ruotolo, G., Nicholls, S. J., Dullea, R., Carvajal-Gonzalez, S., & Sacks, F. M. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.121.317181 · Cited by 52
Effects of Diet on 10-Year Atherosclerotic Cardiovascular Disease Risk (from the DASH Trial)
Jeong, S. Y., Wee, C. C., Kovell, L. C., Plante, T. B., Miller, E. R., Appel, L. J., Mukamal, K. J., & Juraschek, S. P. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.10.019 · Cited by 69
Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein
Kon, V., Yang, H., & Fazio, S. (2015) · Archives of Medical Research · doi:10.1016/j.arcmed.2015.05.009 · Cited by 61
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes
Lund, S. S., Tarnow, L., Astrup, A. S., Hovind, P., Jacobsen, P. K., Alibegovic, A. C., Parving, I., Pietraszek, L., Frandsen, M., Rossing, P., et al. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01079.x · Cited by 53
Human genetics of HDL: Insight into particle metabolism and function
Brunham, L. R., & Hayden, M. R. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.01.001 · Cited by 53
Duprez, D. A., Otvos, J. D., Tracy, R. P., Feingold, K. R., Greenland, P., Gross, M. D., Lima, J. A. C., Mackey, R. H., Neaton, J. D., Sanchez, O. A., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002295 · Cited by 55
Bruyndonckx, L., Hoymans, V. Y., Lemmens, K., Ramet, J., & Vrints, C. J. (2016) · Pediatric Research · doi:10.1038/pr.2016.22 · Cited by 59
Shao, B., & Heinecke, J. W. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1402680 · Cited by 59
High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus
He, Y., Kothari, V. M., & Bornfeldt, K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310222 · Cited by 62
Taheri, H., Filion, K. B., Windle, S. B., Reynier, P., & Eisenberg, M. J. (2020) · Cardiology · doi:10.1159/000505365 · Cited by 56
HDL cholesterol concentration or HDL function: which matters?
Barter, P. J., & Rye, K. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx274 · Cited by 55
Self-citationHigh Density Lipoproteins and Diabetes
Cochran, B. J., Ong, K. L., Manandhar, B., & Rye, K. (2021) · Cells · doi:10.3390/cells10040850 · Cited by 61
“7% Decreased glucose Decreased insulin Decreased insulin resistance Decreased HbA1c Ref [12]: Barter et al.”
BackgroundLCAT- targeted therapies: Progress, failures and future
Yang, K., Wang, J., Xiang, H., Ding, P., Wu, T., & Ji, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112677 · Cited by 56
Dysfunctional High-Density Lipoprotein Cholesterol and Coronary Artery Disease: A Narrative Review
Madaudo, C., Bono, G., Ortello, A., Astuti, G., Mingoia, G., Galassi, A. R., & Sucato, V. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090996 · Cited by 67
“Surprisingly, however, trials attempting to demonstrate the beneficial effects of therapies that increase HDL levels, such as CETP inhibitors, have only produced negative results, even leading to an increase in cardiovascular events [31,32].”
BackgroundYoung, P. J., Hodgson, C. L., Dulhunty, J. M., Saxena, M. K., Bailey, M., Bellomo, R., Davies, A., Finfer, S. R., Krüger, P., Lipman, J., et al. (2012) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)01757-x · Cited by 61
Surrogate markers in clinical trials—Challenges and opportunities
Duivenvoorden, R., de Groot, E., Stroes, E. S. G., & Kastelein, J. J. P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.12.009 · Cited by 62
Self-citationChen, S. N., Cilingiroglu, M., Todd, J., Lombardi, R., Willerson, J. T., Gotto, A. M., Ballantyne, C. M., & Marian, A. (2009) · BMC Medical Genetics · doi:10.1186/1471-2350-10-111 · Cited by 51
“In contrast, raising the plasma high HDL-C level, even modestly, with the exception of inhibition of cholesteryl ester transfer protein (CETP) with torcetrapib, protects against atherosclerosis and reduces adverse cardiovascular events [4,8-10].”
High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis
Ossoli, A., Pavanello, C., & Calabresi, L. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.223 · Cited by 65
Lymphocyte activation gene 3 and coronary artery disease
Golden, D., Kolmakova, A., Sura, S. R., Vella, A. T., Manichaikul, A. W., Wang, X., Bielinski, S. J., Taylor, K. D., Chen, Y. I., Rich, S. S., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88628 · Cited by 52
Metadata
- Authors
- Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., & Brewer, B.
- Affiliations
- The Heart Research Institute (AU)
- St Bartholomew's Hospital (GB)
- Karolinska University Hospital (SE)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Hospital Universitario La Paz (ES)
- Columbia University (US)
- Montreal Heart Institute (CA)
- San Francisco General Hospital (US)
- Pfizer (United States) (US)
- University of Wisconsin–Madison (US)
- Columbia University Irving Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2109-2122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2048760408
- Cited by
- 3,139
- References
- 15
- Citations by year
- 2026: 74 · 2025: 91 · 2024: 87 · 2023: 91 · 2022: 107 · 2021: 131 · 2020: 104 · 2019: 152 · 2018: 161 · 2017: 203 · 2016: 224 · 2015: 252 · 2014: 204 · 2013: 243 · 2012: 219
- FWCI
- 193.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- torcetrapib, cholesteryl ester transfer protein inhibition, cardiovascular events, high cardiovascular risk, atorvastatin, HDL cholesterol, LDL cholesterol, potassium, bicarbonate, aldosterone, mortality, off-target effects, drug safety
- MeSH terms
- Atorvastatin, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mortality, Pyrroles, Quinolines, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.